Latest Health News: FDA Approvals, Drug Recalls, and More

The article provides a comprehensive summary of recent health news highlights. It covers FDA approvals, drug recalls, ongoing health crises in war zones, and forecasts in pharmaceutical sectors. Key headlines include new treatments for blood cancer, discontinued lung cancer trials, and projections for companies like Merck, Perrigo, and Novavax.

The U.S. Food and Drug Administration has approved Citius Pharmaceuticals' therapy, Lymphir, for certain adult patients with relapsed cutaneous T-cell lymphoma, the company announced on Thursday. The rare blood cancer treatment comes a year after an initial rejection by the regulator.

In separate news, Merck has halted a trial for a combination immunotherapy drug targeting lung cancer, following an interim analysis that indicated the treatment was unlikely to succeed and had a higher rate of immune-related side effects.

Perrigo has voluntarily recalled 16,500 cans of its infant formula following a regulatory filing last Friday. The recalled products were sold at H-E-B Grocery Company and CVS.

In Gaza, thousands of children, including 3-year-old Yasmine Al-Shanbari, are suffering from skin diseases as the ongoing conflict leaves the enclave with poor sanitation, scarce medicine, and a dysfunctional healthcare system.

Novavax has trimmed its revenue forecast for 2024 and plans to reduce its European footprint ahead of transferring the rights to sell its COVID-19 vaccine to partner Sanofi in 2025. Despite entering the market later than competitors like Pfizer and Moderna, Novavax has struggled to gain a significant market share.

Germany's STIKO vaccine advisory panel recommended new RSV vaccines by GSK and Pfizer for those aged 75 and older. The panel suggests these should ideally be administered before the cold season.

A few North American companies are developing vape-like devices for migraines and respiratory diseases but face an uphill battle to persuade health authorities and patients about their efficacy.

Africa's public health agency is preparing to declare an mpox emergency due to the rapid spread of a new variant across the Democratic Republic of Congo's borders. The viral infection, while generally mild, can cause serious symptoms and even be fatal.

Canadian company Canopy Growth posted smaller-than-expected losses in Q1 due to reduced operational costs and increased demand for medical cannabis. Meanwhile, India's Zydus Lifesciences reported a strong profit driven by high demand for its generic respiratory drugs in North America.